Antecedent  	Antecedent  	 JJ	B-NP
cardiovascular  	cardiovascular  	 JJ	I-NP
disease  	disease  	 NN	I-NP
and  	and  	 CC	O
autoimmunity  	autoimmunity  	 NN	B-NP
in  	in  	 IN	O
Philadelphia-negative  	Philadelphia-negative  	 JJ	B-NP
chronic  	chronic  	 JJ	I-NP
myeloproliferative  	myeloproliferative  	 NNS	I-NP
neoplasms  	neoplasms  	 VBP	I-NP
A  	A  	 DT	O
single  	single  	 JJ	O
institution  	institution  	 NN	B-NP
case-control  	case-control  	 JJ	I-NP
study  	study  	 NN	I-NP
was  	was  	 VBD	O
conducted  	conducted  	 VBN	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
developing  	developing  	 VBG	O
chronic  	chronic  	 JJ	B-NP
myeloproliferative  	myeloproliferative  	 JJ	I-NP
neoplasms  	neoplasms  	 NNS	I-NP
( 	( 	 -LRB-	O
MPNs 	MPNs 	 NNP	B-NP
)  	)  	 -RRB-	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
prior  	prior  	 JJ	O
autoimmune  	autoimmune  	 JJ	B-NP
disease  	disease  	 NN	I-NP
and  	and  	 CC	O
cardiovascular  	cardiovascular  	 JJ	B-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
CVD 	CVD 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Cases  	Cases  	 NNS	O
were  	were  	 VBD	O
323  	323  	 CD	O
MPN  	MPN  	 NN	B-NP
patients  	patients  	 NNS	I-NP
and  	and  	 CC	O
controls  	controls  	 NNS	O
were  	were  	 VBD	O
333  	333  	 CD	O
chronic  	chronic  	 JJ	B-NP
lymphocytic  	lymphocytic  	 JJ	I-NP
leukemia  	leukemia  	 NN	I-NP
( 	( 	 -LRB-	O
CLL 	CLL 	 NNP	B-NP
)  	)  	 -RRB-	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Odds  	Odds  	 NNS	B-NP
ratios  	ratios  	 NNS	I-NP
( 	( 	 -LRB-	O
ORs 	ORs 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
p-values  	p-values  	 JJ	B-NP
using  	using  	 VBG	O
Fischer 	Fischer 	 NNP	O
's  	's  	 POS	O
exact  	exact  	 JJ	O
tests  	tests  	 NNS	O
were  	were  	 VBD	O
calculated 	calculated 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
data  	data  	 NNS	O
was  	was  	 VBD	O
adjusted  	adjusted  	 VBN	O
for  	for  	 IN	O
confounding  	confounding  	 JJ	O
effects  	effects  	 NNS	O
by  	by  	 IN	O
logistic  	logistic  	 JJ	B-NP
regression 	regression 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
significantly  	significantly  	 RB	O
increased  	increased  	 VBN	B-NP
risk  	risk  	 NN	I-NP
of  	of  	 IN	O
MPNs  	MPNs  	 JJ	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
CLL  	CLL  	 NNP	B-NP
was  	was  	 VBD	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
subjects  	subjects  	 NNS	B-NP
with  	with  	 IN	O
a  	a  	 DT	O
prior  	prior  	 JJ	O
history  	history  	 NN	O
of  	of  	 IN	O
any  	any  	 DT	O
autoimmune  	autoimmune  	 JJ	B-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
OR=1.86 	OR=1.86 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
% 	% 	 NN	O
CI  	CI  	 NNP	O
1.16-2.98 	1.16-2.98 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
positive  	positive  	 JJ	B-NP
association  	association  	 NN	I-NP
between  	between  	 IN	O
JAK2-V617F  	JAK2-V617F  	 CD	O
positive  	positive  	 JJ	B-NP
MPN  	MPN  	 NNP	I-NP
and  	and  	 CC	O
any  	any  	 DT	O
autoimmune  	autoimmune  	 JJ	B-NP
disease  	disease  	 NN	I-NP
was  	was  	 VBD	O
observed  	observed  	 VBN	O
at  	at  	 IN	O
follow-up  	follow-up  	 NNP	O
( 	( 	 -LRB-	O
OR=2.62 	OR=2.62 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
1.21-5.67 	1.21-5.67 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
significantly  	significantly  	 RB	O
increased  	increased  	 VBN	B-NP
risk  	risk  	 NN	I-NP
of  	of  	 IN	I-NP
MPN  	MPN  	 NNP	I-NP
compared  	compared  	 VBN	O
to  	to  	 TO	O
CLL  	CLL  	 NNP	B-NP
was  	was  	 VBD	O
also  	also  	 RB	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
subjects  	subjects  	 NNS	B-NP
with  	with  	 IN	O
prior  	prior  	 JJ	O
thromboembolic  	thromboembolic  	 JJ	B-NP
events  	events  	 NNS	I-NP
( 	( 	 -LRB-	O
TE-events 	TE-events 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
OR=2.09 	OR=2.09 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
% 	% 	 NN	O
CI  	CI  	 NNP	O
1.42-3.08 	1.42-3.08 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
MPN  	MPN  	 NNP	B-NP
group 	group 	 NN	I-NP
,  	,  	 ,	O
an  	an  	 DT	O
increased  	increased  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
JAK2-V617F-positive  	JAK2-V617F-positive  	 CD	O
disease  	disease  	 NN	O
was  	was  	 VBD	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
subjects  	subjects  	 NNS	B-NP
with  	with  	 IN	O
prior  	prior  	 JJ	O
TE-events  	TE-events  	 NN	B-NP
( 	( 	 -LRB-	O
OR=2.19 	OR=2.19 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
% 	% 	 NN	O
CI  	CI  	 NNP	O
1.51-3.16 	1.51-3.16 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
discussed  	discussed  	 VBN	O
if  	if  	 IN	O
chronic  	chronic  	 JJ	B-NP
inflammation  	inflammation  	 NN	I-NP
in  	in  	 IN	O
relation  	relation  	 NN	O
to  	to  	 TO	O
autoimmunity  	autoimmunity  	 VB	O
and  	and  	 CC	O
atherosclerosis  	atherosclerosis  	 NNS	B-NP
might  	might  	 MD	O
elicit  	elicit  	 VB	O
mutations  	mutations  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
hematopoietic  	hematopoietic  	 JJ	B-NP
stem  	stem  	 NN	I-NP
cell  	cell  	 NN	I-NP
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
MPNs 	MPNs 	 NNP	B-NP
,  	,  	 ,	O
or  	or  	 CC	O
whether  	whether  	 IN	O
this  	this  	 DT	O
association  	association  	 NN	O
actually  	actually  	 RB	O
reflects  	reflects  	 VBZ	O
a  	a  	 DT	O
long-lasting  	long-lasting  	 JJ	O
pre-MPN-diagnosis  	pre-MPN-diagnosis  	 JJ	B-NP
phase 	phase 	 NN	I-NP
,  	,  	 ,	O
in  	in  	 IN	O
which  	which  	 WDT	O
the  	the  	 DT	O
MPN-disease  	MPN-disease  	 JJ	B-NP
per  	per  	 FW	O
se  	se  	 FW	B-NP
contributes  	contributes  	 FW	O
to  	to  	 TO	O
a  	a  	 DT	O
chronic  	chronic  	 JJ	B-NP
inflammatory  	inflammatory  	 JJ	I-NP
state  	state  	 NN	I-NP
and  	and  	 CC	O
immune  	immune  	 JJ	O
deregulation 	deregulation 	 NN	B-NP
.  	.  	 .	O
